ABT vs COLD · P/E 25, rev $44.33B vs rev $2.67B
Abbott Laboratories (ABT) versus Americold Realty Trust (COLD) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Americold Realty Trust (COLD) is a reit - industrial company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported COLD revenue for 2024-12-31 was $2.67B. Net income was -$94.7M. Revenue was down 0.3% from 2023-12-31 to 2024-12-31. COLD currently screens at market cap $4.75B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. COLD currently screens at market cap $4.75B.
Not investment advice. Open the ABT and COLD stock pages for the full models.
Not investment advice.